Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05163977
Other study ID # SO2106-31005
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 12, 2021
Est. completion date December 2022

Study information

Verified date December 2021
Source Cairo University
Contact Ehab A Abdulmaksoud, Master
Phone 01099192044
Email ehab.a.abdelmaksoud@cu.edu.eg
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to make a step for evaluation and presentation of a safe technique for pancreatico-jejunostomy that help in minimizing post-operative morbidity and mortality in pancreatic cancer patient by comparing Blumgart anastomosis with Cattell warren technique of anastomosis.


Description:

Study Design This study is a randomized prospective clinical trial. Methods of randomization: Randomized block design The objective of the study was to evaluate the effect of Blumgart anastomosis versus Cattell Warren techniques for pancreatico-jejunostomy regarding - Surgical technique - Peri-operative outcome including 1. Length of hospital stay 2. Post-operative pancreatic fistula 3. ICU admission and stay 4. Operative time 5. Other morbidity and mortality Data collection: All data will be collected for each group and will be divided into Patients' factors, intraoperative and postoperative factors. Patients' factors include patients' demographics, co-morbidities, neoadjuvant treatment, Pathology and Biliary drainage. Intra-operative factors include type of Pancreaticoduodenectomy (PD) (Whether classic or PPPD), Operative time in hours and estimated blood loss in ml, pancreatic duct and texture of pancreas. Post-operative factors include the short term post-operative course which will be divided into specific complications (pancreatic leakage, biliary leakage, delayed gastric emptying, 2ry hemorrhage, intra-abdominal collection, deep wound infection, Portal Vein (PV) - Superior Mesenteric Vein (SMV) thrombosis and general surgical complications.


Recruitment information / eligibility

Status Recruiting
Enrollment 90
Est. completion date December 2022
Est. primary completion date December 2022
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Known Pancreatic head cancer diagnosed radiologically. - Operable and borderline pancreatic cancer. - Patients who will undergo upfront surgery and those who received neoadjuvant chemotherapy are included. Exclusion Criteria: - Metastatic patients. - Locally advanced cases. - Patients with comorbidities who are unfit for major surgical procedures. - Patients with very small pancreatic duct where the pancreatic duct can't be identified.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Blumgart Anastomosis
The anti-mesenteric border of the jejunal loop proximal to the hepatico-jejunostomy is brought against the pancreatic stump. With the pancreatic stump retracted by the stay sutures, the transected end of pancreatic duct is first identified and secured by means of a blunt tipped probe. Each trans-pancreatic, suture was performed using a single Polydioxanone (PDS) 3 -0 blunt needle. We usually take 4 sutures, 2 on each side of the duct. The process is repeated in the same manner with the remaining sutures which are tightened at the end to approximate the jejunum loop to the stump. A small stab incision is then made at the anti-mesenteric border of the jejunum and a duct to mucosa anastomosis is constructed using an interrupted 5-0 Prolene. The process is completed by placing each of the retained needles through the seromuscular layer of the anterior jejunal wall and each knot is tied over the jejunal wall which is then warped over the cut end of the stump
Cattell Warren Anastomosis
It is a two layer, interrupted, end to side pancreatico-jejunostomy. First an interrupted sutures between the posterior capsule and the seromuscular layer of the jejunum was constructed using PDS 3-0 , then a duct to mucosa interrupted sutures were taken using PDS 5-0 and finally interrupted sutures between the anterior capsule and the jejunum . The main difference here is that the sutures are taken in a conventional way which is tangential to the pancreatic capsule and parenchyma

Locations

Country Name City State
Egypt The Egyptian National Cancer Institute Cairo

Sponsors (1)

Lead Sponsor Collaborator
Cairo University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary Post-Operative Pancreatic Fistula We used the International Study Group of Pancreatic Fistula (ISGPF) definition which is any measurable pancreatic fluid output after postoperative day 3 (containing more than three times the normal serum amylase level; more than 300 IU/L) with clinical signs of an infection and/or necessitating a change in clinical management. Up to 10 days after the operation
Secondary Biliary leakage Any biliary output via percutaneous drains after the first postoperative day, or detected at a re-laparotomy Up to 10 days after the operation
Secondary Post-Operative bleeding including early and late bleeding (1-3 weeks post-operative) According to ISGPF it is defined as any bleeding from the surgical site with a drop in hemoglobin concentration greater than 3 g/dL with peripheral circulatory impairment requiring medical, surgical, or radiological intervention. 1-3 weeks
Secondary Hospital Stay the post operative hospital stay Immediate after surgery and until the discharge of the patient ,including the readmission within the first 30 days after the operation
Secondary Operative Time Time of the surgical procedure in hours During the operation
Secondary primary or reactionary hemorrhage Bleeding that occurs during or in the first day after the operation During the operation and within the first 24 hours after the operation
See also
  Status Clinical Trial Phase
Terminated NCT02902484 - Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer Phase 1/Phase 2
Completed NCT04008537 - Daily Imaging, Target Identification, and Simulated Computed Tomography-Based Stereotactic Adaptive Radiotherapy Workflow in a Novel Ring Gantry Radiotherapy Device N/A
Recruiting NCT04809935 - EUS-Coeliac Plexus Block Versus Radiofrequency Ablation in Pain Relief of Patients With Malignancy Phase 4
Not yet recruiting NCT03659292 - Effects of Epidural Block on the Prognosis in Patients With Pancreatic Cancer Undergoing Distal Pancreatectomy N/A
Completed NCT03150615 - Enteral Nutrition After Pancreaticoduodenectomy N/A
Recruiting NCT02682394 - Evaluation of Pancreatic Steatosis in Patients With Cancer of Pancreas N/A
Recruiting NCT05566743 - A Study Evaluating Maintenance Therapy After First Line Chemotherapy in Metastatic Cancer Pancreas Phase 2
Not yet recruiting NCT04049461 - Heterotopic Ossification in Abdominal Incision and Pancreatic Cancer
Recruiting NCT04164602 - The Occurence of Pancreatic Cancer Studied in Association With Newly Diagnosed Diabetes in the Elderly
Active, not recruiting NCT04128332 - Pre-operative Stereotactic Ablative Body Radiotherapy Followed by Immediate Surgery for Pancreatic Cancer N/A
Recruiting NCT03536793 - Tumour Regulatory Molecules in Early Pancreatic Cancer Detection
Recruiting NCT02311439 - Induction Chemotherapy, FOLFIRINOX Followed With Concurrent Capecitabine and Radiation Therapy in Inoperable Locally Advanced Cancer of the Pancreas Phase 2/Phase 3
Completed NCT02296736 - The Pre-operative Pathway in Pancreatic Head Malignancy-assessment of the Diagnostic Accuracy of Staging CT Scan
Withdrawn NCT04123574 - A Pilot Study of BXCL701 in Patients With Pancreatic Cancer Early Phase 1
Not yet recruiting NCT03278015 - Phase 2 Trial of Gemcitabine vs S-1 vs Gemcitabine Plus Nab-paclitaxel as Adjuvant Chemotherapy of Post-operative Pancreatic Cancer Patients Phase 2
Active, not recruiting NCT02905578 - A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1) Phase 2
Completed NCT01446458 - Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer Phase 1
Recruiting NCT04677244 - Echo-endoscopy Biopsy Impact on the Circulating Tumor Cell Level N/A
Recruiting NCT04028479 - The Registry of Oncology Outcomes Associated With Testing and Treatment
Recruiting NCT06148298 - Cell-Free DNA Chromatin Immunoprecipitation (ChIP) for Diagnosing Cancer